Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has disclosed compounds acting as Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
Scientists at Emory University and Hadasit Medical Research Services and Development Ltd. have described nuclear receptor ROR-α agonists reported to be useful for the treatment of liver cancer, pancreatitis, diabetes, obesity, immunological disorders, neurological disorders, liver diseases and metabolic diseases, among others.
Beijing Sciwind Biotechnology Co. Ltd. and Sciwind Biosciences Co. Ltd. have divulged glucagon-like peptide 2 receptor (GLP-2R) agonists reported to be useful for the treatment of Crohn’s disease, irritable bowel syndrome, malnutrition, ulcerative colitis, obesity and graft-vs.-host disease.
Shanghai Helioson Pharmaceutical Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin-protein ligase-binding moiety covalently bonded to a Bruton tyrosine kinase (BTK)-targeting moiety through a linker. They are reported to be useful for the treatment of cancer and autoimmune diseases.
Samjin Pharmaceutical Co. Ltd. has synthesized Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of allergy, inflammatory bowel disease, arthritis and migraine.
Intelligen Therapeutics Co. Ltd. and Intelligen Therapeutics Inc. have disclosed macrocyclic compounds acting as TNF-α inhibitors reported to be useful for the treatment of inflammation and autoimmune diseases.
Researchers from the University of California, Davis (UC-Davis) continue to assemble intellectual property in support of their development of methods and techniques which improve the accuracy of wearable sensor technologies.
Guangzhou Fermion Technology Co. Ltd. has described non-receptor tyrosine-protein kinase TYK2 (JH2 domain) inhibitors reported to be useful for the treatment of allergy, autoimmune disease, cancer, dermatological disorders, dry eye, myelofibrosis, neurological disorders and transplant rejection, among others.
Luye Innomind Pharma Shijiazhuang Co. Ltd. has divulged salts of 5-HT2A receptor inverse agonists with improved stability reported to be useful for the treatment of bipolar disorder, depression, Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, sleep disorders, anxiety disorders and schizophrenia.
Haisco Pharmaceutical Group Co. Ltd. has identified crystalline forms of poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
RSS
